Beyond the exploration of potential mechanisms of resistance, Silverman et al. conducted sequencing on a clinical cohort of cholangiocarcinoma (CCA) with FGFR2 rearrangements, providing direct evidence of the response to Pemigatinib targeted therapy. This evidence concerns the gene FGFR2 and cholangiocarcinoma.